Comparison of different Lp (a) elimination techniques: A retrospective evaluation

Transfusion and Apheresis Science

Volumn 41, Issue 1, 2009, Pages 61-65

  Borberg, Helmut ^a  

^a German Haemapheresis Centre   (Germany)

Author keywords

Apheresis therapy; Extracorporeal elimination; Lipoprotein (a); Lp (a); Lp (a) treatment; Lp (a) apheresis

Indexed keywords

LIPOPROTEIN;

APHERESIS; ARTICLE; ATHEROSCLEROSIS; BLOOD FILTRATION; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; LIPOPROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY;

ATHEROSCLEROSIS; BLOOD COMPONENT REMOVAL; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEIN(A); RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 67651225129     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2009.05.014     Document Type: Article

References (53)

1. Utermann G., Haibach C., Trommsdorff M., Kochl S., Lingenhel A., Abe A., and Kraft H.G. Genetic architecture of the atherogenic lipoprotein(a). Ann NY Acad Sci 748 (1995) 301-312
2. Kostner G.M., Wo X., Frank S., Kostner K., Zimmermann R., and Steyrer E. Metabolism of Lp(a): assembly and excretion. Clin Genet 52 5 (1997) 347-354
3. Ogorelkova M., Kraft H.G., Ehnholm C., and Utermann G. Single nucleotide polymorphisms in exons of the apo(a) kringles IV types 6-10 domain affect Lp(a) plasma concentrations and have different patterns in Africans and Caucasians. Hum Mol Genet 10 8 (2001) 815-824
4. Kronenberg F., Steinmetz A., Kostner G.M., and Dieplinger H. Lipoprotein(a) in health and disease. Crit Rev Clin Lab Sci 33 6 (1996) 495-543
5. Kronenberg F., Kronenberg M.F., Kiechl S., Trenkwalder E., Santer P., Oberhollenzer F., Egger G., Utermann G., and Willeit J. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation 100 11 (1999) 1154-1160
6. Kraft H.G., Lingenhel A., Raal F.J., Hohenegger M., and Utermann G. Lipoprotein(a) in homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 20 2 (2000) 522-528
7. Kostner K.M., and Kostner G.M. The physiological role of lipoprotein (a). Drug News Perspect 15 2 (2002) 69-77 [March]
8. Kostner K.M., and Kostner G.M. Lipoprotein(a): still an enigma?. Curr Opin Lipidol 13 4 (2002) 391-396 [Review, August]
9. Ignatescu M., Kostner K., Zorn G., Kneussl M., Maurer G., Lang I.M., and Huber K. Plasma Lp(a) levels are increased in patients with chronic thromboembolic pulmonary hypertension. Thromb Haemost 80 2 (1998) 231-232
10. Christ G., Kostner K., Zehetgruber M., Binder B.R., Gulba D., and Huber K. Plasmin activation system in restenosis: role in pathogenesis and clinical prediction?. J Thromb Thrombolys 7 3 (1999) 277-285
11. Caplice N.M., Panetta C., Peterson T.E., Kleppe L.S., Mueske C.S., Kostner G.M., Broze Jr. G.J., and Simari R.D. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood 98 10 (2001) 2980-2987
12. Buechler C., Ullrich H., Ritter M., Porsch-Oezcueruemez M., Lackner K.J., Barlage S., Friedrich S.O., Kostner G.M., and Schmitz G. Lipoprotein (a) up-regulates the expression of the plasminogen activator inhibitor 2 in human blood monocytes. Blood 97 4 (2001) 981-986
13. Milionis H.J., Elisaf M.S., and Mikhailidis D.P. The effects of lipid-regulating therapy on haemostatic parameters. Curr Pharm Des 9 29 (2003) 2425-2443
14. Marcucci R., Liotta A.A., Cellai A.P., Rogolino A., Gori A.M., Giusti B., Poli D., Fedi S., Abbate R., and Prisco D. Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism. Am J Med 115 8 (2003) 601-605 [December 1]
15. Hoefler G., Harnoncourt F., Paschke E., Mirtl W., Pfeiffer H., and Kostner G.M. Lipoprotein Lp(a). A risk factor for myocardial infarction. Arteriosclerosis 8 4 (1988) 398-401
16. Sandkamp M., Funke H., Schulte H., Kohler E., and Assmann G. Lipoprotein (a) is an independent risk factor for myocardial infarction at a young age. Clin Chem 36 1 (1990) 20-23
17. Watts G.F., Kearney E.M., Taub N.A., and Slavin B.M. Lipoprotein (a) as an independent risk factor for myocardial infarction in patients with common hypercholesterolaemia. J Clin Pathol 46 3 (1993) 267-270
18. Cantin B., Gagnon F., Moorjani S., Despres J.P., Lamarche B., Lupien P.J., and Dagenais D.R. Is lipoprotein (a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol 32 4 (1998) 1132-1134
19. Dahlen G.H., and Stenlund H. Lp(a) lipoprotein is a major risk factor for cardiovascular disease: pathogenic mechanisms and clinical significance. Clin Genet 562 5 (1997) 272-280
20. Bostom A.G., Cupples L.A., Jenner J.L., Ordovas J.M., Seman L.J., Wilson P.W., Schaefer E.J., and Castelli W.P. Elevated plasma lipoprotein (a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA 276 7 (1996) 544-548
21. Fujino A., Watanabe T., Kunii H., Yamaguch N., Yoshinari K., Watanabe Y., Mutou M., Ishikawa S., Ogyuu A., Ashikawa K., and Maruyama Y. Lipoprotein (a) is a potential coronary risk factor. Jpn Circ J 64 1 (2000) 51-56
22. Hopkins P.N., Hunt S.C., Sachreiner P.J., Eckfeldt J.H., Borecki I.B., Ellison C.R., Williams R.R., and Siegmund K.D. Lipoprotein (a) interactions with lipid and non-lipid risk factors in patients with early onset coronary artery disease: results from the NHLBI Family Heart Study. Atherosclerosis 141 2 (1998) 333-345
23. Lingenhel A., Kraft H.G., Kotze M., Peeters A.V., Kronenberg F., Kruse R., and Utermann G. Concentrations of the atherogenic Lp(a) are elevated in FH. Eur J Hum Genet 6 1 (1998) 50-60 [January]
24. Adlouni A., el Messal M., Ghalim N., and Saile R. Apolipoproteins and lipoprotein particles in Moroccan patients with previous myocardial infarction. Int J Clin Lab Res 27 4 (1997) 247-252
25. Von Eckardstein A., Schulte H., Cullen P., and Assmann G. Lipoprotein (a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 37 2 (2001) 434-439
26. Price J.F., Lee A.J., Rumley A., Lowe D.G., and Fowkes F.G. Lipoprotein (a) and development of intermittent claudication and major cardiovascular events in men and women: The Edinburgh Artery Study. Atherosclerosis 157 1 (2001) 241-249
27. Cantin B., Despres J.P., Lamarche B., Moorjani S., Lupien P.J., Bogaty P., Bergeron J., and Dagenais G.R. Association of fibrinogen and lipoprotein (a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study). Am J Cardiol 89 6 (2002) 662-666
28. Kronenberg F., Konig P., Neyer U., Auinger M., Pribasnig A., Lang U., Reitinger J., Pinter G., Utermann G., and Dieplinger H. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 6 1 (1995) 110-120 [July]
29. Kronenberg F., Utermann G., and Dieplinger H. Lipoprotein (a) in renal disease. Am J Kidney Dis 27 1 (1996) 1-25
30. Kronenberg F., Trenkwalder E., Lingenhel A., Friedrich G., Lhotta K., Schober M., Moes N., Konig P., Utermann G., and Dieplinger H. Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation. J Lipid Res 38 9 (1997) 1755-1763 [September]
31. Kronenberg F., Trenkwalder E., Sturm W., Kathrein H., Konig P., Neyer U., Grochenig E., Utermann G., and Dieplinger H. LDL-unbound apolipoprotein(a) and carotid atherosclerosis in hemodialysis patients. Clin Genet 52 5 (1997) 377-386
32. Kostner K.M., Jansen M., Maurer G., and Derfler K. LDL-apheresis significantly reduces urinary apo(a) excretion. Eur J Clin Invest 27 1 (1997) 93-95
33. Kostner K.M., Clodi M., Bodlaj G., Watschinger B., Horl W., Derfler K., and Huber K. Decreased urinary apolipoprotein (a) excretion in patients with impaired renal function. Eur J Clin Invest 28 6 (1998) 447-452 [June]
34. Kerschdorfer L., Konig P., Neyer U., Bosmuller C., Lhotta K., Auinger M., Hohenegger M., Riegler P., Margreiter R., Utermann G., Dieplinger H., and Kronenberg F. Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4 years of follow-up. Atherosclerosis 144 2 (1999) 381-391
35. Cauza E., Kletzmaier J., Bodlaj G., Dunky A., Herrmann W., and Kostner K. Relationship of non-LDL-bound apo(a), urinary apo(a) fragments and plasma Lp(a) in patients with impaired renal function. Nephrol Dial Transplant 18 8 (2003) 1568-1572
36. Sechi L.A., Kronenberg F., De Carli S., Falleti E., Zingaro L., Catena C., Utermann G., and Bartoli E. Association of serum lipoprotein(a) levels and apolipoprotein(a) size polymorphism with target-organ damage in arterial hypertension. JAMA 277 21 (1997) 1689-1695
37. Shi H., Fang J., Yang X., Shen Z., and Zhu X. Lipoprotein (a) concentration and apolipoprotein (a) phenotype in subjects with type 2 diabetes mellitus. Chin Med J 111 11 (1998) 1013-1017
38. Kronenberg F., Auinger M., Trenkwalder E., Irsigler K., Utermann G., and Dieplinger H. Is apolipoprotein(a) a susceptibility gene for type I diabetes mellitus and related to long-term survival?. Diabetologia 42 8 (1999) 1021-1024
39. Labudovic D.D., Toseska K.N., Alabakovska S.B., and Todorova B. Apoprotein(a) phenotypes and plasma lipoprotein(a) concentration in patients with diabetes mellitus. Clin Biochem 36 7 (2003) 545-551 [October]
40. Christopher R., Kailasanatha K.M., Nagaraja D., and Tripathi M. Case-control study of serum lipoprotein (a) and apolipoproteins A-I and B in stroke in the young. Acta Neurol Scan 94 2 (1996) 127-130
41. Cao G.F., Yang Q.D., Liu Y.H., Xu H.W., and Xia J. Lipoprotein (a) and cerebral infarction in young adults. Zhonghua Liu Xing Bing Xue Za Zhi 24 5 (2003) 397-400
42. Schillinger M., Domanovits H., Ignatescu M., Exner M., Bayegan K., Sedivy R., Polterauer P., Laggner A.N., Minar E., and Kostner K. Lipoprotein (a) in patients with aortic aneurysmal disease. J Vasc Surg 36 1 (2002) 25-30
43. Pokrovsky S.N., Adamova I., Afanasieva O.Y., and Benevolenskaya G.F. Immunosorbent for selective removal of lipoprotein (a) from human plasma: in vitro study. Artif Organs 15 2 (1991) 136-140
44. Pokrovsky S.N., Sussekov A.V., Afanasieva O.I., Adamova I.Y., Lyakishev A.A., and Kukharchuk V.V. Extracorporeal immunoadsorption for the specific removal of lipoprotein (a) (Lp(a) apheresis): preliminary clinical data. Chem Phys Lipids 67-68 (1994) 323-330
45. Pokrovsky S.N., Ezhov M.V., Il'ina L.N., Afanasieva O.I., Sinitsyn V.Y., Shiriaev A.A., and Akchurin R.S. Association of lipoprotein(a) excess with early vein graft occlusions in middle-aged men undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 126 4 (2003) 1071-1075
46. Luc G., Bard J.M., Arveiler D., Ferrieres J., Evans A., Amouyel P., Fruchart J.C., and Ducimetiere P. PRIME Study Group lipoprotein (a) as an predictor of coronary heart disease: The Prime Study. Atherosclerosis 163 2 (2002) 377-384
47. Solfrizzi V., Panza F., Colacicco A.M., Capurso D., D'Introno A., Torres F., Baldassare G., and Capurso A. Relation of lipoprotein (a) as coronary risk factor to type 2 diabetes mellitus and low-density lipoprotein cholesterol in patients > or = 65 years of age (The Italian Longitudinal Study on Aging, ILSA). Am J Cardiol 89 7 (2002) 825-829
48. Kostner G.M., and Steinmetz A. Standardization of Lp(a) measurements. Clin Genet 52 5 (1997) 393-397
49. Kostner G.M., Ibovnik A., Holzer H., and Grillhofe H. Preparation of a stable fresh frozen primary lipoprotein[a] (Lp[a]) standard. J Lipid Res 40 12 (1999) 2255-2263
50. Tate J.R., Rifai N., Berg K., Couderc R., Dati F., Kostner G.M., Sakurabayashi I., and Steinmetz A. International Federation of Clinical Chemistry standardization project for the measurement of lipoprotein (a). Phase I: evaluation of the analytical performance of lipoprotein (a) assay systems and commercial calibrators. Clin Chem 44 8 Pt 1 (1998) 1629-1640
51. Tate J.R., Berg K., Couderc R., Dati F., Kostner G.M., Marcovina S.M., Rifai N., Sakurabayashi I., and Steinmetz A. International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) standardization project for the measurement of lipoprotein(a). Phase 2: selection and properties of a proposed secondary reference material for lipoprotein (a). Clin Chem Lab Med 37 10 (1999) 949-958
52. Scholtz C.L., Lingenhel A., Hillermann R., Stander I.A., Kriek J.A., Marais M.P., Odendaal H.J., Kraft H.G., Utermann G., and Kotze M.J. Lipoprotein (a) determination and risk of cardiovascular disease in South African patients with familial hypercholesterolaemia. S Afr Med J 90 4 (2000) 374-378 [April]
53. Seed M., Ayres K.L., Humphries S.E., and Miller G.J. Lipoprotein (a) as a predictor of myocardial infarction in middle-aged men. Am J Med 110 1 (2001) 71-72